Abstract 123P
Background
HER2 is overexpressed in a subset of BTC patients, and recent developments in HER2-targeted agents are expanding therapeutic options. However, accurately assessing HER2 expression is challenging in BTC, especially at a low-expression level. We evaluated HER2 expression as well as TILs density through AI models in BTC.
Methods
Whole-slide images (WSI) of pre-treatment HER2 immunohistochemistry (IHC) slides, matched H&E-stained slides and clinicopathological data were obtained from advanced or metastatic BTC patients at CHA Bundang Medical Center in South Korea, between 2019 and 2022. An AI-powered HER2 analyzer classifies tumor cells by HER2 staining intensity (H0, H1, H2, or H3) and quantifies the cells in each staining category. Then, it calculates HER2 categories (0/1+/2+/3+) following the latest ASCO/CAP HER2 IHC guidelines. For evaluating immune landscape, a separate WSI analyzer identified and quantified. TILs within the cancer epithelium or stroma from H&E-stained slides.
Results
In a total of 328 patients, the AI-scored HER2 categories were 0 in 92 (28.9%), 1+ in 137 (43.1%), 2+ in 68 (21.4%), and 3+ in 21 (6.6%). The overall concordance of HER2 categories between the AI and pathologists’ readings was 75.3%. HER2 3+ rates by AI in intrahepatic, extrahepatic, gallbladder, and Ampulla of Vater are estimated to be 3.1%, 3.4%, 21.4%, and 5.9%, respectively. HER2-expressing tumors (1+, 2+, and 3+) have significantly higher densities of stromal TILs (983.2 ± 1347.5 / mm2) than HER2-negative tumors (683.5 ± 739.7 / mm2, p=0.012) and there were no significant TIL density differences between HER2-high expressing (3+) and low expressing tumors (1+, 2+), which were consistent with either by the AI or pathologists.
Conclusions
AI-powered HER2 scoring showed good agreement with pathologists’ scoring, and HER2-expressing tumors harbored high stromal TIL in BTC. Objective expression analysis and the associated differences in immunogenicity will be important for future treatment strategies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Lunit Inc.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
700P - First-in-human dose-escalating study of ABSK043, a novel and oral small-molecule inhibitor of PD-L1, in patients with advanced solid tumors
Presenter: Adam Cooper
Session: Poster session 17
701P - NCI10221: Phase II multicenter biomarker driven combination trial of copanlisib and nivolumab in patients with molecularly-selected advanced solid tumors (BaCoN)
Presenter: Timothy Yap
Session: Poster session 17
702P - Characterization of germline HLA genotypes in patients (pts) with solid tumors treated with immunotherapy
Presenter: Katerin Rojas Laimito
Session: Poster session 17
703P - Prognostic scores for immunotherapy-based phase one trials (P1T): To GRIm or not to GRIm?
Presenter: Pauline Corbaux
Session: Poster session 17
705P - TIMES: A ctDNA tumor fraction based and externally validated nomogram to predict survival in cancer patients referred for early phase trials
Presenter: Antoine Italiano
Session: Poster session 17
706P - The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway - Safety analysis of the first 126 patients included in the trial
Presenter: Katarina Puco
Session: Poster session 17
707P - Personalised dosing of oral targeted therapies in oncology: The era of therapeutic drug monitoring
Presenter: Maud van der Kleij
Session: Poster session 17
709P - Challenges and opportunities to the implementation of adaptive design in phase III oncology trials: Results from a cross-sectional analysis
Presenter: Andriy Krendyukov
Session: Poster session 17